|
Long-term efficacy of BRAFi/MEKi rechallenge in metastatic melanoma: Report of 9 years of clinical practice. |
|
Anna Malgorzata Czarnecka |
Speakers' Bureau - Bristol-Myers Squibb; MSD; Pierre Fabre |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre |
|
|
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre |
Speakers' Bureau - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre |
Travel, Accommodations, Expenses - MSD; Novartis; Pierre Fabre |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Bristol-Myers Squibb; MSD; Pierre Fabre |
|
|
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Pierre Fabre |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Pierre Fabre |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Pierre Fabre |
|
Grażyna Kamińska-Winciorek |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Pierre Fabre |
|
|
Honoraria - Bristol-Myers Squibb; MSD; Pierre Fabre |
Speakers' Bureau - Bristol-Myers Squibb; MSD; Pierre Fabre |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Pierre Fabre |
|
|
Honoraria - Bristol-Myers Squibb; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Sanofi |
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; MSD; Novartis; Philogen; Pierre Fabre |
Speakers' Bureau - Novartis; Pfizer; Pierre Fabre |
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Orphan Europe; Pierre Fabre |